Useful for public-health prioritization, trial site and recruitment planning, and identifying high-burden regions and demographic groups for PD interventions, but offers minimal mechanistic or translational insights for direct therapeutic discovery.

Valuable for health-policy and care-planning by documenting a growing Parkinson's rehabilitation burden in China, but it provides little mechanistic insight or direct therapeutic targets for drug discovery.

This paper has minimal relevance for Parkinson's therapeutic discovery because it is a cardiology case report without mechanistic, biomarker, or neurodegeneration insights, though it may inform clinicians about pregnancy-specific drug and management considerations that could intersect with comorbid…

Highlights epigenetic alterations as candidate biomarkers and targetable pathways that could inform earlier Parkinson's diagnosis and epigenetic-based interventions, but is a broad, non-Parkinson-specific review with limited immediate actionable therapeutic leads.

Identifies peripheral inflammation as a prognostic biomarker and a translationally relevant pathway that could guide patient stratification and testing of anti-inflammatory or immunomodulatory therapies, though observational design limits causal inference.

Although this is a correction rather than new data, the underlying review concerns bright light therapy—a low-risk, repurposable intervention targeting sleep/circadian dysfunction relevant to PD non-motor symptoms and clinical trial design.

While primarily epidemiological, the region-specific carrier frequencies—especially enrichment of PLA2G6 variants linked to parkinsonism and iron dysregulation—help prioritize genetic screening, patient identification, and follow-up studies of iron-related mechanisms that could inform…

Low direct value for Parkinson's drug discovery, but the case highlights infection-triggered nigral dysfunction and an imaging correlate that could inform studies of secondary parkinsonism and mechanisms of nigral vulnerability.

The retraction means the reported connectivity-based predictor and its implications for DBS-guided treatment of sleep symptoms in PD are unreliable and should not inform therapeutic decisions, though the topic (sleep outcomes and biomarkers for DBS) remains clinically relevant for future valid…

The study presents a brain-targetable, degradation-resistant antioxidant/anti-inflammatory compound with translational potential (intranasal delivery and Nrf2-related mechanism) that could be advanced for neuroprotective PD strategies, though validation in alpha-synuclein models and…

Reinforces the gut–brain axis as a contributor to PD-relevant pathology and implies that targeting peripheral intestinal inflammation (or patient stratification by inflammatory status) may be a more promising therapeutic or preventative approach than relying solely on LRRK2 kinase inhibition for…

Provides synapse- and compartment-specific glycosylation signatures linked to neuroinflammation and defective glycan maturation that could serve as biomarkers and nominate glycosylation enzymes or lectin-mediated pathways as novel therapeutic or targetable mechanisms in PD-related synaptic…

By providing a high-confidence SV atlas and cell-type-resolved functional links at PD-associated loci, this work enables nomination of causal genes and regulatory variants for follow-up target validation and biomarker development, increasing translational opportunities despite not yet delivering…

Highlights a novel, targetable PTM pathway (UFM1 enzymatic cascade) connected to α‑synuclein and tau biology, providing mechanistic hypotheses and biomarker leads that could be translated into Parkinson’s therapeutics after focused experimental validation.

By improving cell-type–resolved detection of regulatory effects of genetic variants in PD, these methods help prioritize causal genes/variants and refine target and biomarker discovery pipelines, increasing translational value even though the work is primarily methodological.

Although it does not report new therapeutic mechanisms, the platform meaningfully enhances decentralized, biomarker-driven Parkinson's research by enabling low-burden standardized data and specimen collection and precise cohort targeting, which can accelerate translational studies and clinical…

The work links region‑specific NAD/energy metabolism deficits and cerebellar bioenergetic adaptation to motor severity, suggesting measurable metabolic biomarkers and potential NAD‑targeted therapeutic or biomarker avenues relevant to Parkinson's‑related basal ganglia vulnerability, though its…

Offers preclinical support that crocin targets neuroprotective pathways relevant to Parkinson's (oxidative stress, inflammation, survival signaling), making it a modestly promising lead for further translational work, though direct disease‑specific mechanisms, pharmacokinetics, safety, and clinical…

This establishes frailty as a useful population-level risk stratification marker that could help identify individuals for surveillance or preventive interventions relevant to Parkinson's disease, but it offers little mechanistic insight or direct therapeutic targets for drug discovery.

Low immediate value for PD therapeutic discovery, but clinically relevant for fracture risk management and suggests a testable biomarker (homocysteine) and adjunctive intervention opportunity rather than a direct disease‑modifying target.

Limited value for discovery of new therapeutics, but modest translational utility for diagnostic stratification and ensuring appropriate treatment and trial enrollment through imaging-based differentiation.

This has minimal direct value for Parkinson's therapeutic discovery but is clinically relevant for transfusion safety in PD patients and highlights a rare immune complication rather than informing PD mechanisms or drug targets.

By linking a PD‑relevant kinase substrate to synaptic hyperactivity, the work identifies the RAB12–LRRK2 axis as a mechanistic entry point for modulating synaptic dysfunction in Parkinson's research, though direct relevance to dopaminergic degeneration, alpha‑synuclein pathology, or clinical…

Useful as a methodological resource for detecting cytoskeletal biomarkers and profiling protein alterations that can support biomarker discovery or target validation related to Parkinson’s-associated cytoskeletal dysfunction, but it is a general methods review with limited PD-specific mechanistic…

Negligible relevance to Parkinson's therapeutic discovery because it is a cardiology case focused on adolescent HCM and shared decision-making with no mechanistic, biomarker, or therapeutic links to Parkinson's disease.